Questions? Feedback? powered by Olark live chat software
All Site

Dr. Lamarche received his Ph.D. in chemistry from Ohio State University, where his research focused on characterizing the DNA repair system encoded by the African Swine Fever Virus.  He subsequently worked as a postdoctoral fellow in the department of Molecular and Cell Biology at the Salk Institute where he studied the biochemistry of DNA double strand break (DSB) repair in mammals, with specific focus on the types of DSBs generated by cancer chemotherapeutics.  He now works as a Senior Scientist at ACEA Biosciences where he focuses on developing and refining real-time cell analysis applications using the xCELLigence technology.

ugm learnmore

brandon acea


Using Cellular Impedance Assays for the Discovery and Development of Novel Cancer Immunotherapies

Critical to the discovery and development of novel immunotherapies is the ability to quantitatively monitor their cancer killing efficacy under physiologically-relevant conditions in vitro. Traditional cell killing assays suffer from drawbacks that prevent them from meeting this need efficiently. In this talk I will describe the use of cellular impedance as a superior means of monitoring the killing of cancer cells in real-time, without the use of labels, and at biologically relevant effector:target ratios. I will show killing of both liquid and solid cancers by diverse approaches, with specific consideration of:

  • CAR-T and NK cells
  • Antibody-based therapies (checkpoint inhibitors and BiTEs)
  • Contributions of the tumor microenvironment
  • Quantification of efficacy (IC50, killing kinetics, etc.)
  • Clinical theranostics/personalized medicine